A proposed class of ill children hit more than 20 pharmaceutical companies with a suit alleging the companies sought to expand the market for opioids to increase their profits while ignoring regulations intended to keep opioids out of the black market.
The Patent Trial and Appeal Board has wiped out an entire Antecip Bioventures II LLC patent covering a drug used to treat bone problems, a ruling that came in a post-grant review prompted by Grunenthal GmbH.
Medtronic PLC unit HeartWare International told a Manhattan federal court on Friday that it will pay $54.5 million to investors to settle allegations that it misled them about the prospects of its MVAD heart pump and overstated its efforts to fix problems with the device.
A California federal judge declined Thursday to order a retrial for an accountant found guilty of helping a venture capitalist siphon $18 million from a fund using false tax returns.
The U.S. Supreme Court on Friday agreed to take a whistleblower False Claims Act case over a U.S. Department of Defense munitions disposal contract to address the issue of whether the "government knowledge" statute of limitations in FCA cases applies only when the government intervenes.
In what the groups are calling the largest tribal complaint in history, the Arctic Slope Native Association has joined the Tanana Chiefs Conference and other Alaska Native tribal health care providers in their federal court suit against drugmakers and distributors over the opioid epidemic.
The newest round of hires in the health and life sciences industries have found homes at Quinn Emanuel Urquhart & Sullivan LLP, Goodwin Procter LLP, Ropes & Gray LLP, Nelson Hardiman LLP, Nichols Liu LLP, K&L Gates LLP, Manatt Phelps & Phillips, Sumner Schick LLP and a handful of companies in need of GCs.
A Texas federal court jury has convicted a Texas man of tax evasion and money laundering conspiracy for selling used prescription medications to a company that would resell them to pharmacies as new.
Tesaro is reportedly considering a sale, Eli Lilly and Co. is mulling selling off a Chinese off-patent drug portfolio, and Technicolor SA is weighing options including selling off part or all of the business.
A California judge on Thursday granted a couple's request to expedite the trial schedule for their lawsuit alleging Monsanto's Roundup and Ranger Pro herbicides gave them cancer, saying their health could impact their ability to pursue their claims and setting the trial for March 18.
Global law firm Goodwin Procter LLP said it has hired a former Gunderson Dettmer capital markets attorney with extensive experience in the life sciences, telecommunications and technology industries to strengthen Goodwin’s technology companies, life sciences and capital markets practices.
The second South Carolina jury to try and decide if a 30-year-old attorney's fatal mesothelioma was caused by alleged asbestos in Johnson & Johnson talcum powder products on Thursday followed in their predecessors' footsteps and deadlocked, leading to the second mistrial in the case.
A Florida trader dodged prison time for his admitted role in an illicit stock trading operation Thursday when a New Jersey federal judge sentenced him to three years of probation instead, citing his cooperation as a government witness who helped prosecutors net a co-conspirator in the case.
A federal judge has denied three pharmaceutical companies' move to quash subpoenas for information on their plans to make generic substitutes of Allergan’s drug Restasis in multidistrict litigation over its alleged efforts to delay the generic versions’ launch, saying in-house counsel can view the data without compromising confidentiality.
The New York and Connecticut attorneys general can keep sending subpoenas to drugmakers as part of their broader investigations into generic-drug price-fixing, a Pennsylvania federal judge has ruled, despite the drug companies’ concern the investigations were circumventing the discovery process for a sprawling multidistrict litigation.
Centrexion Therapeutics Corp. has reportedly decided to postpone its plans to go public, Apollo Global Management and Gores Group have lobbed bids for engine parts maker Dayco Products, and JD Group is selling FTLife Insurance Co Ltd.
A major player in an alleged conspiracy to bribe doctors to prescribe fentanyl-based drugs from the company Insys Therapeutics is prepared to plead guilty, prosecutors said Wednesday in a filing in Boston federal court.
Johnson & Johnson should pay tens of millions of dollars in recompense for the life of a South Carolina lawyer who succumbed to mesothelioma at 30 after using talcum powder from birth, her husband's lawyers told a jury Wednesday at the close of a retrial in the case.
A Ninth Circuit judge appeared skeptical Wednesday of Bio-Rad Laboratories Inc.'s arguments in favor of overturning an $11 million whistleblower judgment against the company, repeatedly questioning its counsel during a hearing on how an erroneous jury instruction would change the outcome of the verdict.
Gibson Dunn & Crutcher LLP has withdrawn as counsel for Heritage Pharmaceuticals Inc. in the company’s Racketeer Influenced and Corrupt Organizations Act suit against two former executives amid their pending motions to disqualify the firm over its prior ties to them, according to a letter sent by co-counsel to a New Jersey federal judge.
Joshua Peck, incoming marketing director of Hill Wallack LLP, traces the evolution of the chief marketing officer position at law firms and shares insights from three legal marketing pioneers.
The recent legalization of cannabis in Canada can have a significant impact on Canadian citizens employed in related industries that seek admission into the United States. Scott Bettridge of Cozen O’Connor discusses some of the hurdles these professionals may face.
In this monthly series, Amanda Brady of Major Lindsey & Africa interviews management from top law firms about the increasingly competitive business environment. Here we feature Katie DeBord, chief innovation officer at Bryan Cave Leighton Paisner LLP.
The U.S. Food and Drug Administration is expediting the Section 510(k) approval process for Class II medical devices, while courts are accepting the argument that 510(k) approval signifies safety and effectiveness — with implications for punitive damages awards, say Caitlin McHugh and Matthew Smith of Drinker Biddle & Reath LLP.
The Federal Circuit has explained that patent descriptions do not require any particular form of disclosure. However, the court's recent decision in FWP IP v. Biogen points to a heightened scrutiny of descriptions when an applicant amends or adds new claims to cover a competitor’s activities, say Martin Pavane and Darren Mogil of Cozen O’Connor.
With few cases going to trial, many attorneys keep their oral-presentation skills sharp by teaching continuing legal education programs. To avoid giving a CLE that falls flat and damages your reputation, you must fashion a thoughtful message, control its presentation, and nail the beginning and ending, says Daniel Karon of Karon LLC.
Since the oldest members of Generation Z aren’t even finished with law school yet, law firm management is in a unique position to prepare for their entrance into the legal workforce, says Eliza Stoker of Major Lindsey & Africa.
The U.S. Supreme Court's review of Merck v. Albrecht promises to shape the way decisions of regulatory agencies — such as the U.S. Food and Drug Administration’s rejection of a drug manufacturer’s proposed label warning — can be interpreted by juries, say Alan Klein and Matthew Decker at Duane Morris LLP.
Health care featured prominently in the 2018 midterm election campaign. Here, attorneys with Debevoise & Plimpton LLP offer thoughts on what the election results and a divided Congress mean for different sectors of the health care industry.
Pharmaceutical warnings and the way they are regulated and litigated are evolving. Brand-name manufacturers face failure-to-warn suits for generic versions of their products, while generic companies may soon have to update warnings on drugs for which there are no longer brand-name versions, say Chris Essig and Schuyler Ferguson of Winston & Strawn LLP.